SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version and Corrigendum - Archive ouverte HAL Accéder directement au contenu
Ouvrages Année : 2022

SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version and Corrigendum

U. Bernauer
  • Fonction : Auteur
Q. Chaudhry
  • Fonction : Auteur
P.J. Coenraad
  • Fonction : Auteur
M. Dusinska
  • Fonction : Auteur
J. Ezendam
  • Fonction : Auteur
C. L. Galli
  • Fonction : Auteur
B. Granum
  • Fonction : Auteur
E. Panteri
  • Fonction : Auteur
V. Rogiers
  • Fonction : Auteur
M. Stepnik
  • Fonction : Auteur
T. Vanhaecke
  • Fonction : Auteur
S. Wijnhoven
  • Fonction : Auteur
A. Koutsodimou
  • Fonction : Auteur
W. Uter
  • Fonction : Auteur
N. Von Goetz
  • Fonction : Auteur

Résumé

SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version and Corrigendum U. Bernauer, L. Bodin, Q. Chaudhry, P.J. Coenraad, M. Dusinska, J. Ezendam, E. Gaffet, C. L. Galli, B. Granum, E. Panteri, V. Rogiers, Ch. Rousselle, M. Stepnik, T. Vanhaecke, S. Wijnhoven, N. Cabaton, A. Koutsodimou, W. Uter, N. von Goetz A corrigendum to correct the bioavailability oral route for daidzein has been adopted on 11 October 2022 The SCCS adopted this document by written procedure on 11 October 2022 2022 (156 pages) Mise en ligne 13 October 2022 https://health.ec.europa.eu/publications/genistein-and-daidzein_en Publication date : 23 September 2022 Author : Scientific Committee on Consumer Safety (SCCS) Description SCCS members: U. Bernauer (Rapporteur Daidzein), L. Bodin, Q. Chaudhry (Rapporteur Genistein), P.J. Coenraads (Chairperson), M. Dusinska, J. Ezendam, E. Gaffet, C.L. Galli (Rapporteur Genistein), B. Granum (former member), E. Panteri, V. Rogiers, Ch. Rousselle (Rapporteur Daidzein), M. Stepnik, T. Vanhaecke, S. Wijnhoven SCCS external experts: N. Cabaton, A. Koutsodimou, W. Uter, N. von Goetz Contact:SANTE-SCCS@ec.europa.eu On request from: European Commission SCCS Number: SCCS/1641/22 Adopted on: 16 September 2022 A corrigendum to correct the bioavailability oral route for daidzein has been adopted on 11 October 2022 Conclusion of the opinion: (1) In light of the data provided and taking under consideration the concerns related to potential endocrine disrupting properties of phytoestrogens, (a) does the SCCS consider genistein safe when used in cosmetic products up to a maximum concentration of 0.007%? (b) does the SCCS consider daidzein safe when used in cosmetic products up to a maximum concentration of 0.02%? From the safety assessment based on the available relevant data on the aglycone form of genistein and daidzein, and in consideration of the potential endocrine disrupting properties of phytoestrogens, the SCCS considers that: a) the use of genistein (CAS No 446-72-0, EC No 207-174-9) in cosmetic products up to a maximum concentration of 0.007% is safe. b) the use of daidzein (CAS No 486-66-8, EC No 207-635-4) in cosmetic products up to a maximum concentration of 0.02% is safe. (2) Alternatively, according to the SCCS what is the maximum concentration of genistein and daidzein that is considered safe for individual and combined use in cosmetic products? / (3) Does the SCCS have any further scientific concerns with regard to the use of genistein and daidzein or other related phytoestrogens in cosmetic products? / Keywords: SCCS, scientific opinion, genistein (CAS No 446-72-0, EC No 207-174-9), daidzein (CAS No 486-66-8, EC No 207-635-4), Regulation 1223/2009
Fichier non déposé

Dates et versions

hal-03814470 , version 1 (14-10-2022)

Identifiants

  • HAL Id : hal-03814470 , version 1

Citer

U. Bernauer, L. Bodin, Q. Chaudhry, P.J. Coenraad, M. Dusinska, et al.. SCCS OPINION on Genistein and Daidzein - SCCS/1641/22 Final version and Corrigendum. Scientific Committee for Consumer Safety (SCCS, EC). , 2022, Scientific Committee for Consumer Safety (SCCS, EC). ⟨hal-03814470⟩
21 Consultations
0 Téléchargements

Partager

Gmail Facebook X LinkedIn More